HC Wainwright Forecasts Inozyme Pharma Q1 Earnings

Inozyme Pharma, Inc. (NASDAQ:INZY) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Inozyme Pharma in a research note issued on Friday, January 10th. HC Wainwright analyst E. White expects that the company will earn ($0.43) per share for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.44) EPS and Q4 2025 earnings at ($0.50) EPS.

A number of other analysts have also commented on the stock. Wedbush reaffirmed an “outperform” rating and set a $12.00 price objective on shares of Inozyme Pharma in a research note on Friday. Piper Sandler reduced their price objective on shares of Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research note on Wednesday, November 6th. Wells Fargo & Company reduced their price objective on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday. Finally, Raymond James started coverage on shares of Inozyme Pharma in a research note on Thursday, December 12th. They set an “outperform” rating and a $26.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $18.33.

Inozyme Pharma Price Performance

INZY stock opened at $1.72 on Monday. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma has a one year low of $1.61 and a one year high of $7.80. The firm has a market capitalization of $110.49 million, a PE ratio of -1.10 and a beta of 1.35. The firm has a 50-day moving average of $2.96 and a two-hundred day moving average of $4.36.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05.

Hedge Funds Weigh In On Inozyme Pharma

Large investors have recently made changes to their positions in the business. Eventide Asset Management LLC increased its holdings in Inozyme Pharma by 5.0% in the third quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock worth $21,623,000 after buying an additional 198,216 shares during the last quarter. Samlyn Capital LLC increased its holdings in Inozyme Pharma by 15.0% in the second quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock worth $14,943,000 after buying an additional 437,622 shares during the last quarter. State Street Corp increased its holdings in Inozyme Pharma by 5.0% in the third quarter. State Street Corp now owns 1,050,420 shares of the company’s stock worth $5,494,000 after buying an additional 50,386 shares during the last quarter. Geode Capital Management LLC increased its holdings in Inozyme Pharma by 1.7% in the third quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company’s stock worth $6,126,000 after buying an additional 19,499 shares during the last quarter. Finally, Barclays PLC increased its holdings in Inozyme Pharma by 261.4% in the third quarter. Barclays PLC now owns 76,730 shares of the company’s stock worth $401,000 after buying an additional 55,497 shares during the last quarter. Institutional investors and hedge funds own 88.30% of the company’s stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.